Advertisement
Advertisement
FLGT
Fulgent Genetics, Inc. Common Stock
18.57
USDSponsored
-0.09
-0.48%
Aug 18, 15:59 UTC -4
Closed
After-Market
18.58
+0.01
+0.05%
FLGT Earnings Reports
Positive Surprise Ratio
FLGT beat 28 of 40 last estimates.
70%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$88.03M
/-$0.66
Implied change from Q2 26 (Revenue/ EPS)
+3.09%
/+15.79%
Implied change from Q3 25 (Revenue/ EPS)
+4.71%
/-571.43%
Fulgent Genetics, Inc. Common Stock earnings per share and revenue
On Jul 30, 2026, FLGT reported earnings of -0.57 USD per share (EPS) for Q2 26, missing the estimate of -0.46 USD, resulting in a -23.61% surprise. Revenue reached 85.39 million, compared to an expected 95.88 million, with a -10.94% difference. The market reacted with a -18.11% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.66 USD, with revenue projected to reach 88.03 million USD, implying an increase of 15.79% EPS, and increase of 3.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Claritev Corporation
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$4.21
Actual
-$3.49
Surprise
+17.12%
Senseonics Holdings, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.63
Actual
-$0.63
Surprise
+1.13%
CapsoVision, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.15
Surprise
-12.02%
Insight Molecular Diagnostics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.24
Actual
-$0.23
Surprise
+7.67%
CareCloud, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.06
Actual
$0.06
Surprise
-7.12%
Neuraxis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.19
Surprise
+41.79%
P3 Health Partners Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.93
Actual
-$0.63
Surprise
+67.41%
Hims & Hers Health, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.01
Actual
-$0.10
Surprise
-599.30%
Heartflow, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+48.68%
MDxHealth SA Ordinary Shares
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.18
Surprise
+9.04%
FAQ
What were Fulgent Genetics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Fulgent Genetics, Inc. Common Stock reported EPS of -$0.57, missing estimates by -23.61%, and revenue of $85.39M, -10.94% below expectations.
How did the market react to Fulgent Genetics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -18.11%, changed from $20.21 before the earnings release to $16.55 the day after.
When is Fulgent Genetics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Fulgent Genetics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Fulgent Genetics, Inc. Common Stock is expected to report EPS of -$0.66 and revenue of $88.03M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement